Custom-Made cancer vaccine shows promise in early trial
NCT ID NCT06614140
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if the vaccine is safe and can trigger an immune response against their cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen peptide vaccine with Poly-ICLC and checkpoint inhibitors
What this could lead to
If successful, this could point toward a personalized treatment that trains the immune system to attack a patient's specific cancer, potentially controlling tumor growth or reducing recurrence risk.
What could go wrong
This is a very early, small trial with only 8 participants, so results may not apply to all patients. The vaccine is personalized and complex, and it may not work for everyone or could cause side effects from immune activation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vejthani Hospital
Bangkok, 10240, Thailand